-- Conference call to be held Monday, August 14, 2023, at 8:30 a.m. ET --
BRIDGEWATER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its second quarter 2023 financial results and provide a commercial update on Monday, August 14, 2023, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows:
Date Monday, August 14, 2023Time 8:30 a.m. ETRegister* (audio only) Click hereWebcast (live and replay) https://ir.rvlpharma.com/ under the “Investors & News” section
* Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.
IMPORTANT SAFETY INFORMATION
Use UPNEEQ with caution in patients with cerebral or coronary insufficiency or Sjögren’s syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop. Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution. In-Site Communications, Inc.
E: lwilson@insitecony.com